Cannabinoid chemistry: an overview

  • Lumír O. Hanuš
  • Raphael Mechoulam
Part of the Milestones in Drug Therapy MDT book series (MDT)


Ajulemic Acid Noid Receptor Cannabidiolic Acid Tetrahydrocannabinolic Acid Cannabigerolic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Li HL (1974) An archeological and historical account of cannabis in China. Econ Bot 28: 437–448Google Scholar
  2. 2.
    Wood TB, Spivey WTN, Easterfield TH (1896) Charas, the resin of Indian hemp. J Chem Soc 69: 539–546Google Scholar
  3. 3.
    Wood TB, Spivey WTN, Easterfield TH (1899) Cannabinol. Part I. J Chem Soc 75: 20–36Google Scholar
  4. 4.
    Cahn RS (1932) Cannabis indica resin, Part III. The constitution of Cannabinol. J Chem Soc 1342–1353Google Scholar
  5. 5.
    Jacob A, Todd AR (1940) Cannabis indica. Part II. Isolation of cannabidiol from egyptian hashish. Observations on the structure of cannabinol. J Chem Soc 649–653Google Scholar
  6. 6.
    Ghosh R, Todd AR, Wilkinson S (1940) Cannabis indica, Part V. The synthesis of cannabinol. J Chem Soc 1393–1396Google Scholar
  7. 7.
    Adams R, Baker BR, Wearn RB (1940) Structure of cannabinol. III. Synthesis of cannabinol, l-Hydroxy-3-n-amyl-6,6,9-trimethyl-6-dibenzopyran. J Am Chem Soc 62: 2204–2207CrossRefGoogle Scholar
  8. 8.
    Adams R, Wolff H, Cain CK, Clark JH (1940) Structure of cannabidiol. V. Position of the alicyclic double bonds. JAm Chem Soc 62: 2215–2219CrossRefGoogle Scholar
  9. 9.
    Adams R, Loewe S, Pease DC, Cain CK, Wearn RB, Baker BR, Wolff H (1940) Structure of cannabidiol. VIII. Position of the double bonds in cannabidiol. Marihuana activity of tetrahydrocannabinols. JAm Chem Soc 62: 2566–2567CrossRefGoogle Scholar
  10. 10.
    Adams R, Baker BR (1940) Structure of cannabidiol. VII. A method of synthesis of a tetrahydrocannabinol which possesses marihuana activity. JAm Chem Soc 62: 2405–2408CrossRefGoogle Scholar
  11. 11.
    Adams R, Pease DC, Cain CK, Baker BR, Clark JH, Wolff H, Wearn RB (1940) Conversion of cannabidiol to a product with marihuana activity. A type reaction fo synthesis of analogous substances. Conversion of cannabidiol to cannabinol. JAm Chem Soc 62: 2245–2246CrossRefGoogle Scholar
  12. 12.
    Ghosh R, Todd AR, Wilkinson S (1940) Cannabis indica, Part IV. The synthesis of some tetrahydrodibenzopyran derivatives. J Chem Soc 1121–1125Google Scholar
  13. 13.
    Krejčí Z, Šantavý F (1955) Isolace dalsˇích látek z listí indickeho konopí Cannabis sativa L. Acta Univ Palacki Olomuc 6: 59–66Google Scholar
  14. 14.
    Kabelík J, Krečí Z, Šantavý F (1960) Cannabis as a medicament. Bull Narc 12: 5–23Google Scholar
  15. 15.
    Mechoulam R, Shvo Y (1963) The structure of cannabidiol. Tetrahedron 19: 2073–2078CrossRefPubMedGoogle Scholar
  16. 16.
    Gaoni Y, Mechoulam R (1964) Isolation, structure, and partial synthesis of an active constituent of hashish. JAm Chem Soc 86: 1646–1647CrossRefGoogle Scholar
  17. 17.
    Mechoulam R, Gaoni Y (1967) The absolute configuration of Δ1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett 8: 1109–1111CrossRefGoogle Scholar
  18. 18.
    Hively RL, Mosher WA, Hoffmann FW (1966) Isolation of trans6-tetrahydrocannabinol from marijuana. JAm Chem Soc 88: 1832–1833CrossRefGoogle Scholar
  19. 19.
    Gaoni Y, Mechoulam R (1964) The structure and synthesis of cannabigerol, a new hashish constituent. Proc Chem Soc 82Google Scholar
  20. 20.
    Gaoni Y, Mechoulam R (1966) Cannabichromene, a new active principle in hashish. Chem Commun 20–21Google Scholar
  21. 21.
    Claussen U, v Spulak F, Korte F (1966) Zur chemischen Klassifizierung von Pflanzen XXXI. Haschisch X. Cannabichromen, ein neuer Haschisch-Inhaltsstoff. Tetrahedron 22: 1477–1479CrossRefGoogle Scholar
  22. 22.
    Crombie L, Ponsford R (1968) Hashish components. Photochemical production of cannabicyclol from cannabichromene. Tetrahedron Lett 9: 5771–5772CrossRefGoogle Scholar
  23. 23.
    Mechoulam R, Gaoni Y (1965) The isolation and structure of cannabinolic, cannabidiolic and cannabigerolic acids. Tetrahedron 21: 1223–1229CrossRefPubMedGoogle Scholar
  24. 24.
    Korte F, Haag M, Claussen U (1966) Tetrahydrocannabinol-carbonsdiure, ein neuer Haschisch-Inhaltsstoff. Angew Chem 77, 862Google Scholar
  25. 25.
    Yamauchi T, Shoyama Y, Aramaki H, Azuma T, Nishioka I (1967) Tetrahydrocannabinolic acid a genuine substance of tetrahydrocannabinol. Chem Pharm Bull 15, 1075PubMedGoogle Scholar
  26. 26.
    Mechoulam R, Ben-Zvi Z, Yagnitinsky B, Shani A (1969) A new tetrahydrocannabinolic acid. Tetrahedron Lett 10: 2339–2341CrossRefGoogle Scholar
  27. 27.
    Krejčí Z, Šantavý F (1975) Isolation of two new cannabinoid acids from Cannabis sativa L. of Czechoslovak origin. Acta Univ Olomuc, Fac Med 74: 161–166Google Scholar
  28. 28.
    Shani A, Mechoulam R (1974) Cannabielsoic acids. Isolation and synthesis by a novel oxidative cyclization. Tetrahedron 30: 2437–2446CrossRefGoogle Scholar
  29. 29.
    Gohda H, Narimatsu S, Watanabe K, Yamamoto I, Yoshimura H (1987) The formation mechanism of cannabielsoin from cannabidiol with guinea-pig hepatic-microsomal enzymes. J Pharm Sci 76: S32Google Scholar
  30. 30.
    Mechoulam R, Ben-Zvi Z (1969) Carboxylation of resorcinols with methyl magnesium carbonate. Synthesis of cannabinoid acids. Chem Commun 343–344Google Scholar
  31. 31.
    Mechoulam R, Gaoni Y (1967) Recent advances in the chemistry of hashish. In: L Zechmeister (ed.): Progress in the chemistry of organic natural products (Fortschritte der Chemie Organischer Naturstoffe), vol. XXV, Springer Verlag, Wien, 175–213Google Scholar
  32. 32.
    Mechoulam R, ed (1973) Marijuana. Chemistry, Metabolism, Pharmacology and Clinical Effects. Academic Press, New YorkGoogle Scholar
  33. 33.
    Turner CE, Elsohly MA, Boeren EG (1980) Constituents of Cannabis sativa L. 17. A review of the natural constituents. JNat Prod 43: 169–234CrossRefGoogle Scholar
  34. 34.
    Hanuš L (1987) Biogenesis of cannabinoid substances in the plant. Acta Univ Palacki Olomuc, Fac Med 116: 47–53Google Scholar
  35. 35.
    Taura F, Morimoto S, Shoyama Y, Mechoulam R (1995) First direct evidence for the mechanism of delta(1)-tetrahydrocannabinolic acid biosynthesis. J Am Chem Soc 117: 9766–9767CrossRefGoogle Scholar
  36. 36.
    Turner CE, Hadley K (1973) Constituents of Cannabis sativa L. II. Absence of cannabidiol in an African variant. J Pharm Sci 62: 251–255PubMedGoogle Scholar
  37. 37.
    KrejčÍ Z, Hanug L, Yoshida T, Braenden OJ (1975) The effect of climatic and ecologic conditions upon the formation and the amount of cannabinoid substances in the cannabis of various provenance. Acta Univ Olomuc, Fac Med 74: 147–160Google Scholar
  38. 38.
    Holley JH, Hadley KW, Turner CE (1975) Constituents of Cannabis sativa L. XI: Cannabidiol and cannabichromene in samples of known geographical origin. J Pharm Sci 64: 892–895PubMedGoogle Scholar
  39. 39.
    Morimoto S, Komatsu K, Taura F, Shoyama Y (1997) Enzymological evidence for cannabichromenic acid biosynthesis. J Nat Prod 60: 854–857CrossRefGoogle Scholar
  40. 40.
    Kushima H, Shoyama Y, Nishioka I (1980) Cannabis. XII. Variations of cannabinoid contents in several strains of Cannabis sativa L. with leaf-age, season and sex. Chem Pharm Bull 28: 594–598Google Scholar
  41. 41.
    Devane WA, Dysarz FA 3rd Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605–613PubMedGoogle Scholar
  42. 42.
    Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946–1949PubMedGoogle Scholar
  43. 43.
    Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231: 313–314CrossRefPubMedGoogle Scholar
  44. 44.
    Hanuš L, Gopher A, Almog S, Mechoulam R (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36: 3032–3034CrossRefPubMedGoogle Scholar
  45. 45.
    Mechoulam R, Ben-Shabat S, Hanug L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to the peripheral cannabinoid receptors. Biochem Pharmacol 50: 83–90CrossRefPubMedGoogle Scholar
  46. 46.
    Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K (1995) 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89–97CrossRefPubMedGoogle Scholar
  47. 47.
    Hanug L, Abu-Lafi S, Fride E, Breuer A, Shalev DE, Kustanovich I, Vogel Z, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, a novel endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98: 3662–3665CrossRefPubMedGoogle Scholar
  48. 48.
    Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, Waku K, Sugiura T (2003) Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem 85: 1374–1381CrossRefPubMedGoogle Scholar
  49. 49.
    Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao JQ, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301: 1020–1024CrossRefPubMedGoogle Scholar
  50. 50.
    Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ et al. (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors Proc Natl Acad Sci USA 99: 8400–8405CrossRefPubMedGoogle Scholar
  51. 51.
    Bezuglov V, Bobrov M, Gretskaya N, Gonchar A, Zinchenko G, Melck D, Bisogno T, Di Marzo V, Kuklev D, Rossi JC et al. (2001) Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg Med Chem Lett 11: 447–449CrossRefPubMedGoogle Scholar
  52. 52.
    Bisogno T, Melck D, Bobrov MY, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo V (2000) N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. J Biochem 351: 817–824CrossRefGoogle Scholar
  53. 53.
    Walker JM, Krey JF, Chu CJ, Huang SM (2002) Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 121: 159–172CrossRefPubMedGoogle Scholar
  54. 54.
    Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686–91CrossRefPubMedGoogle Scholar
  55. 55.
    Burstein SH, Rossetti RG, Yagen B, Zurier RB (2000) Oxidative metabolism of anandamide. Prostag Oth Lipid M 61: 29–41CrossRefGoogle Scholar
  56. 56.
    Johnson MR, Melvin LS (1983) 2-Hydroxy-4-(substituted) phenyl cycloalkanes and derivatives. US Patent 4,371,720, Pfizer IncGoogle Scholar
  57. 57.
    Melvin LS, Johnson MR, Milne GM (1983) A cannabinoid derived analgesic (CP-55,940). In: Abstracts of Papers, 186th Natl. Meet. American Chemical. Soc., Washington, D.C., August 1983. American Chemical Society, Washington, D.C., Abstr. MEDI, 2Google Scholar
  58. 58.
    Johnson MR, Melvin LS (1986) The discovery of nonclassical cannabinoid analgetics. In: R Mechoulam (ed.): Cannabinoids as therapeutic agents. CRC Press, Boca Raton, FL, pp 121–145Google Scholar
  59. 59.
    Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat-brain. Mol Pharmacol 34: 605–613PubMedGoogle Scholar
  60. 60.
    Gerard CM, Mollereau C, Vassart G, Parmentier M (1991) Molecular-cloning of a human cannabinoid receptor which is also expressed in testis. J Biochem 279: 129–134Google Scholar
  61. 61.
    Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Jarbe TUC, Hiltunen AJ, Consroe P (1988) Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 44: 762–764PubMedGoogle Scholar
  62. 62.
    Mechoulam R, Lander N, Breuer A, Zahalka J (1990) Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative. Tetrahedron: Asymmetry 1: 315–319CrossRefGoogle Scholar
  63. 63.
    Little PJ, Compton DR, Mechoulam R, Martin B (1989) Stereochemical effects of 11-OH-delta-8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behavior 32: 661–666CrossRefGoogle Scholar
  64. 64.
    Järbe TUC, Hiltunen AJ, Mechoulam R (1989) Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-OH-delta-8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exper Ther 250: 1000–1005Google Scholar
  65. 65.
    Devane WA, Breuer A, Sheskin T, Jarbe TUC, Eisen M, Mechoulam R (1992) A novel probe for the cannabinoid receptor. J Med Chem 35: 2065–2069CrossRefPubMedGoogle Scholar
  66. 66.
    Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle A, Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 35: 3135–3141CrossRefPubMedGoogle Scholar
  67. 67.
    Burstein SH (2000) Ajulemic Acid (CT3): A potent analog of the acid metabolites of THC. Curr Pharmaceut Design 6: 1339–1345CrossRefGoogle Scholar
  68. 68.
    Recht LD, Salmonsen R, Rosetti R, Jang T, Pipia G, Kubiatowski T, Karim P, Ross AH, Zurier R, Litofsky NS, Burstein S (2001) Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol 62: 755–763CrossRefPubMedGoogle Scholar
  69. 69.
    Liu JL, Li H, Burstein SH, Zurier RB, Chen JD (2003) Activation and binding of peroxisome proliferator-activated receptor γ by synthetic cannabinoid ajulemic acid. Mol Pharmacol 63: 983–992CrossRefPubMedGoogle Scholar
  70. 70.
    Bidinger B, Torres R, Rossetti RG, Brown L, Beltre R, Burstein S, Lian JB, Stein GS, Zuriera RB (2003) Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin Immunol 108: 95–102CrossRefPubMedGoogle Scholar
  71. 71.
    Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M (2004) A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in marine collagen-induced arthritis. Arthritis Rheum 50: 985–998CrossRefPubMedGoogle Scholar
  72. 72.
    Bell MR, D’Ambra TE, Kumar V, Eissenstat MA, Herrmann JL Jr, Wetzel JR, Rosi D, Philion RE, Daum SJ, Hlasta DJ et al. (1991) Antinociceptive (aminoalkyl)indoles. J Med Chem 34: 1099–1110CrossRefPubMedGoogle Scholar
  73. 73.
    D’Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC et al. (1992) Conformationally restrained analogs of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35: 124–135CrossRefPubMedGoogle Scholar
  74. 74.
    Eissenstat MA, Bell MR, D’Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM et al. (1995) Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics. JMed Chem 38: 3094–3105CrossRefGoogle Scholar
  75. 75.
    Haycock DA, Kuster JE, Stevenson JI, Ward SJ, D’Ambra T (1990) Characterization of aminoalkylindole binding: selective displacement by cannabinoids. Probl Drug Depend NIDA Res Monogr 105: 304–305Google Scholar
  76. 76.
    Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Nl1iat G, Caput D et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240–244CrossRefPubMedGoogle Scholar
  77. 77.
    Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO et al. (1998) LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284: 291–297PubMedGoogle Scholar
  78. 78.
    Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B et al. (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284: 644–650PubMedGoogle Scholar
  79. 79.
    Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung M, Martin BR, Abood ME (1999) Evaluation of the cannabinoid CB2 receptor-selective antagonist, 2 SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377: 117–125CrossRefPubMedGoogle Scholar
  80. 80.
    HanuĆ L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Fride E, Mechoulam R (1999) HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228–14233CrossRefPubMedGoogle Scholar
  81. 81.
    Panikashvili D, Simeonidou C, Ben-Shabat S, HanuĆ L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527–531CrossRefPubMedGoogle Scholar
  82. 82.
    Mauler F, Mittendorf J, Horváth E, De Vry J (2002) Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-l-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302: 359–368CrossRefPubMedGoogle Scholar
  83. 83.
    De Vry J, Jentzsch KR (2002) Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. J Pharmacol Exp Ther 457: 147–152Google Scholar
  84. 84.
    Mauler F, Hinz V, Augstein KH, Fassbender M, Horvath E (2003) Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res 989: 99–111CrossRefPubMedGoogle Scholar
  85. 85.
    Mauler F Horváth E, De Vry J, Jäger R, Schwarz T Sandmann S, Weinz C, Heinig R, Böttcher M (2003) BAY 38-7271: A Novel Highly Selective and Highly Potent Cannabinoid Receptor Agonist for the Treatment of Traumatic Brain Injury. CNS Drug Reviews 9: 343–358PubMedGoogle Scholar
  86. 86.
    Pharmos Corp. (2002) Bicyclic cannabinoid. Poster, Society for Neuroscience 32nd Annual Meeting, 3–7 November 2002, Orlando, FLGoogle Scholar
  87. 87.
    Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994) (R)-Methanandamide: A chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37: 1889–1893CrossRefPubMedGoogle Scholar
  88. 88.
    Khanolkar AD, Abadji V, Lin S, Hill WAG, Taha G, Abouzid K, Meng Z, Fan P, Makriyannis A (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem 39: 4515–4519CrossRefPubMedGoogle Scholar
  89. 89.
    Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A (1995) AM630, a competitive cannabinoid receptor antagonist. Life Sci 56: 1949–1955CrossRefPubMedGoogle Scholar
  90. 90.
    Hosohata K, Quock RM, Hosohata Y, Burkey TH, Makliyannis A, Consroe P, Roeske WR, Yamamura HI (1997) AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci 61, PL115–PL118CrossRefPubMedGoogle Scholar
  91. 91.
    Hosohata Y, Quock RM, Hosohata K, Malaiyannis A, Consroe P, Roeske WR, Yamamura HI (1997) AM630 antagonism of cannabinoid-stimulated [S-35]GTP gamma S binding in the mouse brain. Eur J Pharmacol 321, R1–R3CrossRefPubMedGoogle Scholar
  92. 92.
    Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, Gifford AN, Pyatt B, Dewey SL, Makriyannis A (1998) Imaging the Brain Marijuana Receptor: Development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem 70: 417–423PubMedGoogle Scholar
  93. 93.
    Ibrahim MM, Deng H, Zvonok A (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529–10533CrossRefPubMedGoogle Scholar
  94. 94.
    Luk T, Jin WZ, Zvonok A, Lu D, Lin XZ, Chavkin C, Makriyannis A, Mackie K (2004) Identification of a potent and highly efficacious, yet slowly desensitizing CB 1 cannabinoid receptor agonist. Br J Pharm 142: 495–500CrossRefGoogle Scholar
  95. 95.
    Gifford AN, Makriyannis A, Volkow ND, Gatley SJ (2002) In vivo imaging of the brain cannabinoid receptor. Chem Phys Lipids 121: 65–72CrossRefPubMedGoogle Scholar
  96. 96.
    Stoit AR, Lange JH, Hartog AP, Ronken E, Tipker K, Stuivenberg HH, Dijksman JA, Wals HC, Kruse CG (2002) Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem Pharm Bull 50: 1109–1113CrossRefPubMedGoogle Scholar
  97. 97.
    Barth F (1998) Cannabinoid receptor agonists and antagonists. Expert Opin Ther Patents 8: 301–313CrossRefGoogle Scholar
  98. 98.
    Gallant M, Dufresne C, Gareau Y, Guay D, Leblanc Y, Prasit P, Rochette C, Sawyer N, Slipetz DM, Tremblay N et al. (1996) New class of potent ligands for the human peripheral cannabinoid receptor. Bioorg Med Chem Lett 6: 2263–2268CrossRefGoogle Scholar
  99. 99.
    Mussinu JM, Ruiu S, Mule AC, Pau A, Carai MAM, Loriga G, Murineddu G, Pinna GA (2003) Tricyclic pyrazoles. part 1: Synthesis and biological evaluation of novel 1,4-dihydroinde-no[1,2-c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. Bioorg Med Chem 11: 251–263CrossRefPubMedGoogle Scholar
  100. 100.
    Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD, Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39: 3875–3877CrossRefPubMedGoogle Scholar
  101. 101.
    Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR (1999) 3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: Synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7: 2905–2914CrossRefPubMedGoogle Scholar
  102. 102.
    Huffman JW, Bushell SM, Miller JRA, Wiley JL, Martin BR (2002) 1-methoxy-,1-deoxy-11-hydroxy-and 11-Hydroxy-l-methoxy-Δ8-tetrahydrocannabinols: New selective ligands for the CB2 receptor. Bioorg Med Chem 10: 4119–4129CrossRefPubMedGoogle Scholar
  103. 103.
    Lange JHM, Coolen HKAC, van Stuivenberg HH, Dijksman JAR, Herremans AHJ, Ronken E, Keizer HG, Tipker K, McCreary AC, Veerman W et al. (2004) Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem 47: 627–643CrossRefPubMedGoogle Scholar
  104. 104.
    Hertzog DL (2004) Recent advances in the cannabinoids. Expert Opin Ther Patents 14: 1435–1452CrossRefGoogle Scholar
  105. 105.
    Brain C T, Dziadulewicz E K, Hart T W (2003) Chinazolinonderivate und deren verwendung als CB-agonisten. Novartis AG (CH); Novartis Pharma GMBH (AT): W003066603.Google Scholar
  106. 106.
    Makriyannis A, Liu Q (2003) Heteroindane: Eine neue klasse hochwirksamer cannabimimetischer liganden. Univ. Connecticut (US): W003035005.Google Scholar
  107. 107.
    Kozlowski J A, Shankar B B, Shih N Y, Tong L (2004) Cannabinoid receptor agonists. Schering Corp. (US): W02004000807.Google Scholar
  108. 108.
    Kozlowski J A, Shih N Y, Lavey B J, Rizvi R K, Shankar B B, Spitler J M, Tong L, Wolin R, Wong M K (2004) Cannabinoid receptor ligands. Schering Corp. (US): W02004014825.Google Scholar
  109. 109.
    Page D, Walpole Ch, Yang H (2004) Preparation of benzimidazolecarboxamides as CB2 receptor agonists for treating pain and other disorders. AstraZeneca AB (Swed.): W004035548Google Scholar
  110. 110.
    Makriyannis, A., Lai, X Z, Lu D (2004) Preparation of novel biphenyl and biphenyl-like cannabinoids with binding affinities for the CB1 and CB2 cannabinoid receptor. Univ. Connecticut (US): W004017920.Google Scholar
  111. 111.
    Martin B R, Razdan R K (2003) Cannabinoids. Virginia Commonwealth Univ. (US): W003091189.Google Scholar
  112. 112.
    Makriyannis A, Deng H (2002) Novel cannabimimetic ligands. Univ. Connecticut (US): W002058636.Google Scholar
  113. 113.
    Kai H, Murashi T, Tomida M (2002) Medicinal composition containing 1,3-thiazine derivative. Shionogi ⇐p; Co. Ltd (JP): W002072562.Google Scholar
  114. 114.
    Yasui K, Morioka Y, Hanasaki K (2002) Antipruritics. Shionogi ⇐p; Co. Ltd (JP): W003070277.Google Scholar
  115. 115.
    Tada Y, Iso Y, Hanasaki K (2002) Pyridone derivative having affinity for cannabinoid 2-type receptor. Shionogi & Co. Ltd (JP): W002053543.Google Scholar
  116. 116.
    Ferrarini PL, Calderone V, Cavallini T, Manera C, Saccomanni G, Pani L, Ruiu S, Gessa GL (2004) Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptor. Bioorg Med Chem 12: 1921–1933CrossRefPubMedGoogle Scholar
  117. 117.
    Huffman JW, Zengin G, Wu MJ, Lu J, Hynd G, Bushell K, Thompson ALS, Bushell S, Tartal C, Hurst DP et al. (2005) Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg Med Chem 13: 89–112CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2005

Authors and Affiliations

  • Lumír O. Hanuš
    • 1
  • Raphael Mechoulam
    • 1
  1. 1.Department of Medicinal Chemistry and Natural Products, Medical FacultyThe Hebrew University of JerusalemJerusalemIsrael

Personalised recommendations